21 CFR § 330.11 - NDA deviations from applicable monograph.

---
identifier: "/us/cfr/t21/s330.11"
source: "ecfr"
legal_status: "authoritative_unofficial"
title: "21 CFR § 330.11 - NDA deviations from applicable monograph."
title_number: 21
title_name: "Food and Drugs"
section_number: "330.11"
section_name: "NDA deviations from applicable monograph."
chapter_name: "FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES"
subchapter_number: "D"
subchapter_name: "DRUGS FOR HUMAN USE"
part_number: "330"
part_name: "OVER-THE-COUNTER (OTC) HUMAN DRUGS WHICH ARE GENERALLY RECOGNIZED AS SAFE AND EFFECTIVE AND NOT MISBRANDED"
positive_law: false
currency: "2026-04-05"
last_updated: "2026-04-05"
format_version: "1.1.0"
generator: "[email protected]"
authority: "21 U.S.C. 321, 351, 352, 353, 355, 360, 360fff-6, 371."
regulatory_source: "39 FR 11741, Mar. 29, 1974, unless otherwise noted."
cfr_part: "330"
---


# 330.11 NDA deviations from applicable monograph.

A new drug application requesting approval of an OTC drug deviating in any respect from a monograph that has become final shall be in the form required by § 314.50 of this chapter, but shall include a statement that the product meets all conditions of the applicable monograph except for the deviation for which approval is requested and may omit all information except that pertinent to the deviation.

[39 FR 11741, Mar. 29, 1974, as amended at 55 FR 11581, Mar. 29, 1990]